BRIEF-Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
September 28, 2016 at 08:23 AM EDT
* Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy
